DK2076289T3 - Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider - Google Patents
Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider Download PDFInfo
- Publication number
- DK2076289T3 DK2076289T3 DK08742861.1T DK08742861T DK2076289T3 DK 2076289 T3 DK2076289 T3 DK 2076289T3 DK 08742861 T DK08742861 T DK 08742861T DK 2076289 T3 DK2076289 T3 DK 2076289T3
- Authority
- DK
- Denmark
- Prior art keywords
- erbb
- drugs
- methods
- treating cancer
- cancer resistance
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92338407P | 2007-04-13 | 2007-04-13 | |
| PCT/US2008/004804 WO2008127710A2 (en) | 2007-04-13 | 2008-04-11 | Methods for treating cancer resistant to erbb therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2076289T3 true DK2076289T3 (da) | 2015-02-09 |
Family
ID=39561970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08742861.1T DK2076289T3 (da) | 2007-04-13 | 2008-04-11 | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8715665B2 (da) |
| EP (2) | EP2076289B1 (da) |
| JP (3) | JP5926487B2 (da) |
| AU (1) | AU2008239594B2 (da) |
| CA (1) | CA2683559C (da) |
| DK (1) | DK2076289T3 (da) |
| ES (1) | ES2529790T3 (da) |
| WO (1) | WO2008127710A2 (da) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200706804B (en) * | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| WO2007056118A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| EP2129396B1 (en) | 2007-02-16 | 2013-08-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| DK2076289T3 (da) * | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
| US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| JP2011513427A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック， インコーポレイテッド | ｃ−ｍｅｔ及びＥＧＦＲアンタゴニストの併用療法 |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| EP2915532B1 (en) | 2008-06-17 | 2016-10-19 | Wyeth LLC | Antineoplastic combinations containing hki-272 and vinorelbine |
| CN115990181A (zh) | 2008-08-04 | 2023-04-21 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| EP2318548B1 (en) * | 2008-08-15 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Methods and systems for predicting response of cells to a therapeutic agent |
| US20110135651A1 (en) * | 2008-08-19 | 2011-06-09 | Children's Hospital Medical Center | Method and composition for enhancing hematopoietic stem cell mobilization |
| MX2011003363A (es) * | 2008-10-01 | 2011-04-27 | Ludwig Inst Cancer Res | Metodos para el tratamiento de cancer. |
| MX2011008584A (es) | 2009-02-12 | 2012-01-27 | Kyowa Hakko Kirin Co Ltd | Composiciones combinacionales y metodos para el tratamiento del cancer. |
| CA2755789C (en) | 2009-04-06 | 2016-01-19 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
| CA2783743C (en) * | 2009-12-11 | 2022-10-04 | Wyeth Llc | Phosphatidylinositol-3-kinase pathway biomarkers |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| JP6320753B2 (ja) | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| EP2575880B1 (en) | 2010-05-27 | 2019-01-16 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| US20110301194A1 (en) * | 2010-06-02 | 2011-12-08 | Arqule, Inc. | Method for Determining Treatment Efficacy |
| US8580764B2 (en) | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| WO2012030896A2 (en) * | 2010-09-01 | 2012-03-08 | Arqule, Inc. | Methods for treatment of non-small cell lung cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| KR20140002711A (ko) * | 2010-12-23 | 2014-01-08 | 네스텍 소시에테아노님 | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| EP2797957B1 (en) | 2011-11-23 | 2019-06-19 | MedImmune, LLC | Binding molecules specific for her3 and uses thereof |
| MX2014011987A (es) * | 2012-04-03 | 2014-11-10 | Novartis Ag | Combinaciones de inhibidores de cinasa de tirosina y su uso. |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| SMT201800624T1 (it) | 2012-11-21 | 2019-01-11 | Janssen Biotech Inc | Anticorpi egfr/c-met bispecifici |
| CN105264084A (zh) | 2013-01-14 | 2016-01-20 | 中央研究院 | 静默egfr表达的脱氧核糖核酸酶 |
| WO2014182521A1 (en) * | 2013-05-06 | 2014-11-13 | Medimmune, Llc | Diagnostic methods and treatments for cancer |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| WO2015057545A2 (en) | 2013-10-14 | 2015-04-23 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CA2943329A1 (en) | 2014-03-24 | 2015-10-01 | Genentech, Inc. | Cancer treatment with c-met antagonists and correlation of the latter with hgf expression |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| KR101751371B1 (ko) * | 2014-06-25 | 2017-06-27 | 연세대학교 원주산학협력단 | 3,4,5-트리하이드록시벤조산, 이의 유도체 또는 이의 염을 유효성분으로 포함하는 수용체 티로신 키나아제 저해제 내성 항암제 조성물 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| AU2016304856B8 (en) | 2015-08-10 | 2021-02-18 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to BET bromodomain inhibitors |
| WO2017201156A1 (en) * | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
| US10662235B2 (en) | 2016-06-21 | 2020-05-26 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type III domain binding molecules |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| KR102568559B1 (ko) | 2016-12-14 | 2023-08-18 | 얀센 바이오테크 인코포레이티드 | Cd8a-결합 섬유결합소 iii형 도메인 |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| CA3131654A1 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| EP4045061A4 (en) | 2019-10-14 | 2024-04-17 | ARO Biotherapeutics Company | CD71-BINDING FIBRONECTIN TYPE III DOMAINS |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| US12239710B2 (en) | 2021-04-14 | 2025-03-04 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| MX2023012128A (es) | 2021-04-14 | 2024-01-11 | Aro Biotherapeutics Company | Dominios tipo iii de la fibronectina que se unen a cd71. |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4716432A (en) | 1986-04-24 | 1987-12-29 | Eastman Kodak Company | Exposure control apparatus |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US5556750A (en) | 1989-05-12 | 1996-09-17 | Duke University | Methods and kits for fractionating a population of DNA molecules based on the presence or absence of a base-pair mismatch utilizing mismatch repair systems |
| US6008031A (en) | 1989-05-12 | 1999-12-28 | Duke University | Method of analysis and manipulation of DNA utilizing mismatch repair systems |
| US6551784B2 (en) | 1989-06-07 | 2003-04-22 | Affymetrix Inc | Method of comparing nucleic acid sequences |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| CA2118806A1 (en) | 1991-09-18 | 1993-04-01 | William J. Dower | Method of synthesizing diverse collections of oligomers |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
| JP3939338B2 (ja) | 1991-11-22 | 2007-07-04 | アフィメトリックス， インコーポレイテッド | ポリマー合成に対する組合わせの戦略 |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| DE69334351D1 (de) | 1992-02-06 | 2011-05-12 | Novartis Vaccines & Diagnostic | Biosynthetisches Bindeprotein für Tumormarker |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| AU687736B2 (en) | 1992-05-11 | 1998-03-05 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| DE69503126T2 (de) | 1994-05-05 | 1998-11-12 | Beckman Instruments Inc | Repetitive oligonukleotide matrix |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| JP2000501615A (ja) | 1995-12-15 | 2000-02-15 | アマーシャム・ライフ・サイエンス・インコーポレーテッド | 酵素増幅中に生じる変異配列の検出および除去のためのミスマッチ修復系を用いる方法 |
| DE69739909D1 (de) | 1996-03-26 | 2010-07-29 | Michael S Kopreski | Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden |
| WO1997043611A1 (en) | 1996-05-16 | 1997-11-20 | Affymetrix, Inc. | Systems and methods for detection of labeled materials |
| US5869245A (en) | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
| ID19609A (id) | 1996-07-13 | 1998-07-23 | Glaxo Group Ltd | Senyawa-senyawa heterosiklik |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| EP0998306A1 (en) | 1997-07-24 | 2000-05-10 | Inex Pharmaceuticals Corp. | Liposomal compositions for the delivery of nucleic acid catalysts |
| AU1287799A (en) | 1997-10-31 | 1999-05-24 | Affymetrix, Inc. | Expression profiles in adult and fetal organs |
| US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6269846B1 (en) | 1998-01-13 | 2001-08-07 | Genetic Microsystems, Inc. | Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays |
| US6428752B1 (en) | 1998-05-14 | 2002-08-06 | Affymetrix, Inc. | Cleaning deposit devices that form microarrays and the like |
| ES2656439T3 (es) | 1998-02-23 | 2018-02-27 | Wisconsin Alumni Research Foundation | Aparato para síntesis de matrices de sondas de ADN |
| US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
| DK2020408T3 (da) | 1998-05-29 | 2013-09-30 | Sugen Inc | Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4562286B2 (ja) | 1998-12-10 | 2010-10-13 | ブリストル−マイヤーズ スクウィブ カンパニー | 抗体模倣物および他の結合タンパク質のタンパク質骨格 |
| US6232068B1 (en) | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| CA2366459A1 (en) | 1999-03-26 | 2000-10-05 | Affymetrix, Inc. | Universal arrays |
| WO2001077350A2 (en) | 2000-04-07 | 2001-10-18 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
| EA005525B1 (ru) | 2000-06-22 | 2005-04-28 | Пфайзер Продактс Инк. | Замещенные бициклические производные для лечения аномального роста клеток |
| AU1325102A (en) | 2000-10-16 | 2002-04-29 | Phylos Inc | Protein scaffolds for antibody mimics and other binding proteins |
| EA012079B3 (ru) | 2001-01-05 | 2018-07-31 | Пфайзер Инк. | Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| EP1444365A4 (en) | 2001-10-25 | 2005-07-20 | Gorilla Genomics Inc | ASYMMETRIC PCR WITH NUCLEASE-FREE POLYMERASE OR NUCLEASERESISTENT MOLECULAR BEACONS |
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| JP4695588B2 (ja) | 2003-02-26 | 2011-06-08 | スージェン， インク． | プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
| WO2005118876A2 (en) | 2004-06-04 | 2005-12-15 | Genentech, Inc. | Egfr mutations |
| GEP20094845B (en) | 2004-08-26 | 2009-11-25 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| ME01788B (me) | 2004-08-26 | 2011-02-28 | Pfizer | Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza |
| US20060084691A1 (en) * | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| ZA200706804B (en) * | 2005-02-03 | 2008-10-29 | Gen Hospital Corp | Method for treating gefitinib resistant cancer |
| US20080234265A1 (en) * | 2005-03-11 | 2008-09-25 | The Regents Of The University Of Colorado | Histone Deacetylase Inhibitors Sensitize Cancer Cells to Epidermal Growth Factor Inhibitors |
| WO2006108048A1 (en) * | 2005-04-05 | 2006-10-12 | The General Hospital Corporation | Method for predicting responsiveness to drugs |
| AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| CA2610661A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| WO2007002325A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| EP1937837A2 (en) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
| GB0517387D0 (en) * | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| US20100255004A1 (en) | 2007-04-13 | 2010-10-07 | Dana Farber Cancer Institute | Receptor tyrosine kinase profiling |
| DK2076289T3 (da) * | 2007-04-13 | 2015-02-09 | Dana Farber Cancer Inst Inc | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
-
2008
- 2008-04-11 DK DK08742861.1T patent/DK2076289T3/da active
- 2008-04-11 ES ES08742861.1T patent/ES2529790T3/es active Active
- 2008-04-11 JP JP2010503084A patent/JP5926487B2/ja active Active
- 2008-04-11 AU AU2008239594A patent/AU2008239594B2/en active Active
- 2008-04-11 US US12/450,826 patent/US8715665B2/en active Active
- 2008-04-11 EP EP08742861.1A patent/EP2076289B1/en active Active
- 2008-04-11 EP EP14189064.0A patent/EP2851091B1/en active Active
- 2008-04-11 CA CA2683559A patent/CA2683559C/en active Active
- 2008-04-11 WO PCT/US2008/004804 patent/WO2008127710A2/en not_active Ceased
-
2014
- 2014-04-18 US US14/256,418 patent/US20140296100A1/en not_active Abandoned
- 2014-05-09 JP JP2014097474A patent/JP2014141530A/ja active Pending
-
2015
- 2015-12-11 US US14/965,923 patent/US11008620B2/en active Active
-
2016
- 2016-03-01 JP JP2016039191A patent/JP2016121176A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2851091A1 (en) | 2015-03-25 |
| ES2529790T3 (es) | 2015-02-25 |
| AU2008239594B2 (en) | 2013-10-24 |
| EP2076289B1 (en) | 2014-11-12 |
| US8715665B2 (en) | 2014-05-06 |
| US20120225870A1 (en) | 2012-09-06 |
| US20170073760A1 (en) | 2017-03-16 |
| JP2014141530A (ja) | 2014-08-07 |
| US11008620B2 (en) | 2021-05-18 |
| WO2008127710A3 (en) | 2008-12-04 |
| EP2076289A2 (en) | 2009-07-08 |
| JP5926487B2 (ja) | 2016-05-25 |
| EP2851091B1 (en) | 2017-12-27 |
| US20140296100A1 (en) | 2014-10-02 |
| JP2016121176A (ja) | 2016-07-07 |
| JP2010523680A (ja) | 2010-07-15 |
| AU2008239594A1 (en) | 2008-10-23 |
| CA2683559A1 (en) | 2008-10-23 |
| WO2008127710A2 (en) | 2008-10-23 |
| CA2683559C (en) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2076289T3 (da) | Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider | |
| DK2076540T3 (da) | Hidtil ukendte anti-cd38-antistoffer til behandling af cancer | |
| BRPI0810206A2 (pt) | Método de tratar câncer | |
| DK3289876T3 (da) | Forbindelser til behandling af cancer | |
| BRPI0918760A2 (pt) | compostos morfinanos | |
| DK3517534T3 (da) | Forbindelser, der er anvendelige til behandling af cancer | |
| EP2214542A4 (en) | ELECTROMANUAL DISPENSER | |
| DK2061561T3 (da) | Sammensætninger til behandling af cancer | |
| PL2452709T3 (pl) | Kaniula | |
| DK2107917T3 (da) | Injektionssted til injektion af lægemiddel | |
| DE602008005894D1 (de) | Kondensierte imidazole zur krebsbehandlung | |
| DK2125025T3 (da) | Multifunktionelle medikamentbærere | |
| DK2101805T3 (da) | Integrinligander til anvendelse i behandling af cancer | |
| DK3276004T3 (da) | Fremgangsmåder til behandling af kronisk nyresygdom | |
| DK2152885T3 (da) | Polynukleotidmarkører | |
| BRPI0917684A2 (pt) | método terapêutico homeopático | |
| BRPI0922884A2 (pt) | compostos para tratamento de câncer | |
| DK2173831T3 (da) | Brøndbehandling | |
| BRPI0809678A2 (pt) | Métodos | |
| BRPI0924067A2 (pt) | compostos de quinazolina substituída | |
| BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
| BRPI0811597A2 (pt) | compostos de arilamida pirimidona | |
| DK2124547T6 (da) | Fremgangsmåde til behandling af cancer | |
| DK2131841T3 (da) | Fremgangsmåder til behandling af akut smerte | |
| BRPI0818598A2 (pt) | agentes terapêuticos - 802 |